INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTGlobeNewsWire • 06/10/25
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceBusiness Wire • 06/05/25
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a TurnaroundZacks Investment Research • 06/03/25
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data ReleaseSeeking Alpha • 05/30/25
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.Barrons • 05/30/25
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile FailureInvestors Business Daily • 05/30/25
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival EndpointBenzinga • 05/30/25
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global StudyBusiness Wire • 05/30/25
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?Zacks Investment Research • 05/26/25
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should KnowZacks Investment Research • 05/06/25